Important Note

Tufts ended funding for its Open Courseware initiative in 2014. We are now planning to retire this site on June 30, 2018. Content will be available for Tufts contributors after that date. If you have any questions about this please write to

Tufts OpenCourseware
Author: Hedy Smith

1. History

Key elements include:

  • severity of bleeding
  • duration of bleeding, lifelong versus new
  • family history
  • drug history
  • what type of bleeding mucocutaneous vs muscle and joint bleeds
  • surgeries and experience with past dental work
  • menstrual and obstetric history
  • delayed vs immediate
  • need for transfusion or iron supplementation related to bleeding

2. Assays

Bleeding time: evaluates primary hemostasis

  • Prolonged in platelet disorders (quantitative and qualitative), von Willebrand's disease, connective tissue disorders
  • Controversial! Not very specific. Does not correlate with bleeding before procedures.

Prothrombin time PT (INR): measures the time taken for VIIa to complex with tissue factor (TF) to form a clot, i.e., the extrinsic pathway of coagulation

  • Prolongation indicative of VII deficiency or VIIa inhibitor
  • Congenital VII deficiency is rare and most cases are acquired in the context of liver disease or Vit K deficiency seen in newborn and with Vit K antagonists such as Warfarin

Activated Partial thromboplastin time (aPTT): measures the time taken for clotting in the intrinsic pathway

  • Prolongation is indicative of:
    • factor deficiency (XI, IX, VIII)
    • Marked prolongation of XII deficiency but not associated with bleeding
    • Antiphospholipid antibody
    • Factor (VIII, IX, XI) inhibitor
    • Drug (heparin)

Prolongation of PT and aPTT

  • Deficiency or or inhibitor of factors X, V, II (prothrombin), i.e., the common pathway factors
  • Fibrinogen deficiency (<80 mg/dl)
  • High doses of anticoagulants
  • Elevated in DIC

Thrombin time

  • Measures conversion of fibrinogen to fibrin by thrombin (IIa)
  • elevated in DIC, dysfibrinogenemias or hypofibrinogenemias, heparin

Factor XII deficiency

  • Bleeding without prolongation of PT or PTT
  • High incidence of intracranial hemorrhage, umbilical stump hemorrhage and women with spontaneous abortions
  • Does not prolong the aPTT so have screen for deficiency with clot solubility assay or assay for factor level

Factor Assay

  • Quantitates the amount of factor in a given individual

Mixing studies

  • Indicated for prolongation in PT or aPTT
  • Allows one to determine whether elevation in these tests is causes by factor deficiency or inhibitor
  • Patient's abnormal plasma is mixed in 1:1 ratio with normal plasma and abnormal test (PT or PTT) is repeated. Possible results include:
    • Normalization of aPTT or PT at time zero that remains normal at 2 hours is diagnostic of a factor deficiency or inhibitor of von Willebrand's factor (VWF)
    • Normalization at time zero with prolongation on incubation implies the presence of an inhibitor (an acquired antibody)
    • No or partial correction at time zero, with aPTT prolonging with incubation suggestive of antiphospholipid antibody

von Willebrand's screening

  • Factor VIII assay
  • VWF antigen (VWF:Ag) most commonly by ELISA
  • Ristocetin cofactor activity (VWF:RCo)
  • VWF multimer analysis

Inhibitor Assay / Bethesda Assay

  • Serial dilutions of the patient's plasma mixed in 50:50 ratio with normal plasma, followed by assay for the factor that is being inhibited
  • Expressed as a Bethesda titre with one Bethesda unit (BU) being the amount of the inhibitor (i.e., the dilution of the patient's plasma) that neutralizes 50% of the factor in the normal plasma

Other points

  • Vit K dependent coagulation factors: II, VII, IX, X, protein C and Protein S
  • Be aware that infants are deficient in Vit K dependent factors